Compare HSIC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSIC | LNTH |
|---|---|---|
| Founded | 1932 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 4.9B |
| IPO Year | 1996 | 2014 |
| Metric | HSIC | LNTH |
|---|---|---|
| Price | $74.02 | $74.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $84.50 | $83.20 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.21 | N/A |
| EPS | 3.27 | ★ 3.41 |
| Revenue | ★ $13,201,995,000.00 | $343,374,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $3.64 | $13.47 |
| P/E Ratio | ★ $22.09 | $22.42 |
| Revenue Growth | ★ 5.94 | 3.62 |
| 52 Week Low | $60.56 | $47.27 |
| 52 Week High | $89.29 | $108.86 |
| Indicator | HSIC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 45.49 |
| Support Level | $72.81 | $70.73 |
| Resistance Level | $74.85 | $83.70 |
| Average True Range (ATR) | 1.88 | 3.07 |
| MACD | -0.44 | -0.93 |
| Stochastic Oscillator | 28.69 | 14.79 |
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.